|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bob Wieden and Chun Wang, PhD, discuss how significant challenges, coupled with the complexity and diversity of new pharmaceuticals, have fueled the development of a novel polymeric drug delivery platform that overcomes a great many bioavailability and delivery obstacles.
|
|
|
Catherine Hanley, Vice President & Interim CDMO Business Unit Head at Emergent BioSolutions, discusses the company’s plans for current and future CDMO operations and client partnership opportunities.
|
|
|
Fran DeGrazio explains how experienced and focused collaborators can provide guidance, support services, manpower, and intellect to make it easier to achieve all the goals needed in delivering a drug to a patient.
|
|
|
Ameya Deshpande, MS, says for APIs that are compatible with HME, careful attention to the formulation quality attributes that include excipient selection, dosage form design, analytical testing, and stability are required to maximize the efficacy and quality of the final product.
|
|
|
|
|
|
|
|
|

At Gattefossé, each excipient is designed to meet a unique set of formulation and functionality objectives while conforming to the highest safety, quality, and regulatory standards. Product applications include solubility and bioavailability enhancers; sustained/controlled release matrix formers; protective coatings or taste masking agents for actives; emulsifying bases for topical dosage forms; skin penetration and permeation enhancers; and carriers for suppository bases and vaginal pessaries. Among our renown products are Compritol, Labrafil, Gelucire, Labrasol, Capryol, Lauroglycol, Precirol, Tefose, and Suppocire series. Globally established for safety and pharmaceutical qualifications, many of these excipients are also found in pediatric dosage forms. Click here for more.
|
|
|
|
|
|
 |
|
Revive Therapeutics Ltd. recently announced it has filed an application with the US FDA to receive Orphan Drug Designation (ODD) for Bucillamine for the prevention of ischemia–reperfusion injury (IRI) during liver….
|
|
 |
|
Diffusion Pharmaceuticals Inc. recently announced it has dosed the first participants in its Altitude Trial. The trial will evaluate the company’s lead product candidate, trans sodium crocetinate (TSC)….
|
|
 |
|
Decibel Therapeutics recently announced that Regeneron has extended the research term of its collaboration with the company to discover and develop gene therapies for hearing loss…..
|
|
 |
|
Cytovia Therapeutics, Inc. and Cellectis recently announced they have expanded their collaboration of TALEN gene-edited iPSC-derived NK and CAR-NK cells to include new CAR target and….
|
|
 |
|
ImmunityBio, Inc. recently announced the expansion of the company’s cancer and infectious disease vaccine programs to include self-amplifying self-adjuvating RNA (SASA-RNA), recombinant protein vaccine candidates, and potent adjuvant formulations that….
|
|
 |
|
Artizan Biosciences, Inc. and Biohaven Therapeutics Ltd. recently announced the companies are initiating a therapeutic discovery and development program in Parkinson’s disease (PD), to exploit recent….
|
|
|
|
|
Upcoming eNewsletter Features:
December 10 – Prefilled Syringes
December 17 – Injection Devices
|
|
|
|
|
|
|
|